Citigroup reissued their buy rating on shares of TESARO (NASDAQ:TSRO) in a report issued on Wednesday, December 20th, MarketBeat reports. Citigroup currently has a $135.00 target price on the biopharmaceutical company’s stock, down from their prior target price of $216.00.
A number of other research firms also recently weighed in on TSRO. Barclays started coverage on TESARO in a research report on Monday, October 23rd. They set an equal weight rating and a $135.00 target price on the stock. ValuEngine cut shares of TESARO from a hold rating to a sell rating in a research note on Tuesday, October 10th. Jefferies Group reiterated a hold rating and issued a $124.00 target price on shares of TESARO in a research note on Friday, November 3rd. HC Wainwright restated a buy rating and issued a $158.00 price objective on shares of TESARO in a research report on Thursday, October 26th. Finally, Morgan Stanley restated an overweight rating and issued a $165.00 price objective (down previously from $181.00) on shares of TESARO in a research report on Wednesday, November 8th. Three analysts have rated the stock with a sell rating, nine have issued a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of Hold and a consensus price target of $152.64.
Shares of TESARO (TSRO) traded down $4.33 during trading hours on Wednesday, hitting $71.66. The company had a trading volume of 1,545,103 shares, compared to its average volume of 1,011,073. The company has a current ratio of 4.73, a quick ratio of 4.35 and a debt-to-equity ratio of 0.34. TESARO has a twelve month low of $71.50 and a twelve month high of $192.94. The stock has a market capitalization of $3,940.00, a price-to-earnings ratio of -8.50 and a beta of 1.51.
TESARO (NASDAQ:TSRO) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.16) by $0.69. TESARO had a negative return on equity of 93.39% and a negative net margin of 251.22%. The company had revenue of $142.77 million for the quarter, compared to analyst estimates of $130.57 million. During the same period last year, the company earned ($1.72) earnings per share. The business’s revenue was up 740.3% compared to the same quarter last year. sell-side analysts anticipate that TESARO will post -8.19 earnings per share for the current fiscal year.
In other TESARO news, SVP Martin H. Jr. Huber sold 829 shares of the stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $85.24, for a total transaction of $70,663.96. Following the transaction, the senior vice president now owns 8,101 shares in the company, valued at approximately $690,529.24. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 34.60% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of TSRO. Bank of Montreal Can boosted its position in shares of TESARO by 156.5% during the 2nd quarter. Bank of Montreal Can now owns 5,863 shares of the biopharmaceutical company’s stock worth $820,000 after acquiring an additional 3,577 shares in the last quarter. Aperio Group LLC boosted its position in TESARO by 4.5% in the second quarter. Aperio Group LLC now owns 3,658 shares of the biopharmaceutical company’s stock valued at $512,000 after buying an additional 156 shares in the last quarter. Great West Life Assurance Co. Can raised its stake in shares of TESARO by 156.5% during the second quarter. Great West Life Assurance Co. Can now owns 9,620 shares of the biopharmaceutical company’s stock valued at $1,344,000 after acquiring an additional 5,869 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. bought a new position in shares of TESARO during the second quarter valued at $685,000. Finally, First Trust Advisors LP raised its stake in TESARO by 223.0% during the second quarter. First Trust Advisors LP now owns 83,836 shares of the biopharmaceutical company’s stock worth $11,725,000 after buying an additional 57,883 shares during the last quarter.
WARNING: “TESARO (NASDAQ:TSRO) Given “Buy” Rating at Citigroup” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/11/citigroup-reaffirms-buy-rating-for-tesaro-tsro.html.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.